FIND

researchers

DISCOVER

relevant articles

PROMOTE

your research

now for free

Antonio Arrivi

Research Profile

Procedures

Chemicals & Drugs

Concepts & Ideas

Disorders

Phenomena

Karnofsky Performance Status

Co-author Network

Publications

TOP 3
Enrique Aranda; Antonio Arrivi; M Galán; A Irigoyen; J L Manzano; M J Mendez; Carles Pericay; F Rivera; M J Safont; Javier Sastre; M Valladares-Ayerbes; Eduardo Díaz-Rubio
Phase II open-label study of erlotinib in combination with gemcitabine in unresectable and/or metastatic adenocarcinoma of the pancreas: relationship between skin rash and survival (Pantar study).
Eduardo Díaz-Rubio; Carlos Fernández-Martos; Auxiliadora Gómez España; Encarnación González; José Luis Manzano; Eugenio Marcuello; Purificación Martínez de Prado; Bartomeu Massutí; Clara Montagut; Margarita Reboredo; Fernando Rivera; M José Safont; Javier Sastre; Enrique Aranda; Antonio Arrivi; Inmaculada Bando; Manuel Benavides; Andrés Cervantes
Role of Kras status in patients with metastatic colorectal cancer receiving first-line chemotherapy plus bevacizumab: a TTD group cooperative study.
Javier Sastre; Josep M Tabernero; Manuel Valladares; Marta Vidaurreta; Albert Abad; Enrique Aranda; Antonio Arrivi; Manuel Benavides; Carlos Fernández-Martos; Manuel Gallén; Auxiliadora Gómez España; Encarnación González; M Luisa Maestro; Eugenio Marcuello; Bartomeu Massuti; Fernando Rivera; Eduardo Díaz-Rubio
Circulating tumor cell count is a prognostic factor in metastatic colorectal cancer patients receiving first-line chemotherapy plus bevacizumab: a Spanish Cooperative Group for the Treatment of Digestive Tumors study.

Register for free to view:

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the research activity
of experts around the globe

Geonetwork of Antonio Arrivi (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

All Publications

2012: Enrique Aranda; Antonio Arrivi; M Galán; A Irigoyen; J L Manzano; M J Mendez; Carles Pericay; F Rivera; M J Safont; Javier Sastre; M Valladares-Ayerbes; Eduardo Díaz-Rubio
Phase II open-label study of erlotinib in combination with gemcitabine in unresectable and/or metastatic adenocarcinoma of the pancreas: relationship between skin rash and survival (Pantar study).
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2012;23(7):1919-25.
2012: Eduardo Díaz-Rubio; Carlos Fernández-Martos; Auxiliadora Gómez España; Encarnación González; José Luis Manzano; Eugenio Marcuello; Purificación Martínez de Prado; Bartomeu Massutí; Clara Montagut; Margarita Reboredo; Fernando Rivera; M José Safont; Javier Sastre; Enrique Aranda; Antonio Arrivi; Inmaculada Bando; Manuel Benavides; Andrés Cervantes
Role of Kras status in patients with metastatic colorectal cancer receiving first-line chemotherapy plus bevacizumab: a TTD group cooperative study.
PloS one 2012;7(10):e47345.
2012: Javier Sastre; Josep M Tabernero; Manuel Valladares; Marta Vidaurreta; Albert Abad; Enrique Aranda; Antonio Arrivi; Manuel Benavides; Carlos Fernández-Martos; Manuel Gallén; Auxiliadora Gómez España; Encarnación González; M Luisa Maestro; Eugenio Marcuello; Bartomeu Massuti; Fernando Rivera; Eduardo Díaz-Rubio
Circulating tumor cell count is a prognostic factor in metastatic colorectal cancer patients receiving first-line chemotherapy plus bevacizumab: a Spanish Cooperative Group for the Treatment of Digestive Tumors study.
The oncologist 2012;17(7):947-55.
2012: Eduardo Díaz-Rubio; Rosario Dueñas; Pilar Escudero; Carlos Fernández-Martos; Manuel Gallén; Auxiliadora Gómez España; Encarnación González; Adelaida Lacasta; Marta Llanos; Amelia López-Ladrón; Ferrán Losa; Eugenio Marcuello; Purificación Martínez de Prado; Bartomeu Massutí; Fernando Rivera; Maria J Safont; Javier Sastre; Josep Tabernero; Manuel Valladares; Albert Abad; Antonio Antón; Enrique Aranda; Antonio Arrivi; Manuel Benavides; Andrés Cervantes
First-line XELOX plus bevacizumab followed by XELOX plus bevacizumab or single-agent bevacizumab as maintenance therapy in patients with metastatic colorectal cancer: the phase III MACRO TTD study.
The oncologist 2012;17(1):15-25.
2011: C Grávalos; A Lacasta; J L Manzano; M Salgado; Javier Sastre; R Afonso; V Arrazubi; Antonio Arrivi; J C Cámara; J Capdevila; P García-Alfonso; Auxiliadora Gómez España; Eduardo Díaz-Rubio
Recommendations and expert opinion on the treatment of locally advanced rectal cancer in Spain.
Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico 2011;13(12):862-8.
2010: José-María Roca; Vicente Alonso; Carles Pericay; Pilar Escudero; Antonieta Salud; Ferrán Losa; Luis-Jesús López; Imma Guasch; Miguel Méndez; Guillermo Quintero-Aldana; Carlos Grande; Pilar Vicente; Antonio Arrivi; Cristina Martin; Isabel Moreno; Pilar García; Isabel Antón; Manuel Constenla; Alfonso Yubero; Luis Cirera
Cetuximab given every 2 weeks plus irinotecan is an active and safe option for previously treated patients with metastatic colorectal cancer.
Chemotherapy 2010;56(2):142-6.
2007: Javier De Castro; Amdio Ordóñez; Dolores Isla; Alfredo Sánchez; Antonio Arrivi; José Luis Manzano; Manuel González Barón
Early intervention with epoetin beta prevents severe anaemia in patients with solid tumours receiving platinum-based chemotherapy: results of the NeoPrevent study.
Cancer chemotherapy and pharmacology 2007;59(1):35-42.
2004: Angel Artal-Cortés; Jose Gomez-Codina; Jose Luis Gonzalez-Larriba; Isidoro Barneto; Alfredo Carrato; Dolores Isla; Carlos Camps; Carlos Garcia-Giron; Albert Font; Alfredo Meana; Maria Lomas; Catalina Vadell; Antonio Arrivi; Carmen Alonso; Inmaculada Maestu; Joaquin Campbell; Rafael Rosell
Prospective randomized phase III trial of etoposide/cisplatin versus high-dose epirubicin/cisplatin in small-cell lung cancer.
Clinical lung cancer 2004;6(3):175-83.
2004: David Aguiar; Roberto Pazo; Ignacio Durán; Josefa Terrasa; Antonio Arrivi; Herminio Manzano; Javier Martín; Julio Rifá
Toxic epidermal necrolysis in patients receiving anticonvulsants and cranial irradiation: a risk to consider.
Journal of neuro-oncology 2004;66(3):345-50.
2003: Miquel Nogué-Aliguer; Joan Carles; Antonio Arrivi; Oscar Juan; Lorenzo Alonso; Albert Font; Begoña Mellado; Pilar Garrido; Alberto Sáenz
Gemcitabine and carboplatin in advanced transitional cell carcinoma of the urinary tract: an alternative therapy.
Cancer 2003;97(9):2180-6.